BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30025943)

  • 1. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
    Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
    Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
    Elife; 2017 Oct; 6():. PubMed ID: 28967863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic targets in ARID1A-mutated cancers.
    Bitler BG; Fatkhutdinov N; Zhang R
    Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
    Mandal J; Mandal P; Wang TL; Shih IM
    J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
    Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
    Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
    Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
    Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
    Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.
    Fukumoto T; Magno E; Zhang R
    Mol Cancer Res; 2018 Dec; 16(12):1819-1825. PubMed ID: 30037854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the AT-Rich Interaction Domain 1A Gene (
    Li JJ; Lee CS
    Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
    PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations.
    Bitler BG; Aird KM; Zhang R
    Mol Cell Oncol; 2016 Jan; 3(1):e1032476. PubMed ID: 27308548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
    Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
    Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
    Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SWI/SNF-deficient malignancies of the female genital tract.
    McCluggage WG; Stewart CJR
    Semin Diagn Pathol; 2021 May; 38(3):199-211. PubMed ID: 32978032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.
    Coatham M; Li X; Karnezis AN; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Blake Gilks C; Huntsman DG; Stewart CJ; Postovit LM; Köbel M; Lee CH
    Mod Pathol; 2016 Dec; 29(12):1586-1593. PubMed ID: 27562491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.